Literature DB >> 2310722

Cyclocryotherapy: a review of cases over a 10-year period.

M T Benson1, M E Nelson.   

Abstract

There are conflicting reports on the value of cyclocryotherapy in the management of glaucoma. This retrospective study was carried out to assess the efficacy and complication rate of this procedure. The case notes of all patients undergoing cyclocryotherapy at a single centre over a 10-year period were reviewed. Case records were available for 68 eyes of 64 people. Thirty-eight eyes had neovascular glaucoma, nine had aphakic glaucoma, nine had angle closure glaucoma, three had primary open angle glaucoma, and nine had secondary open angle glaucoma. The mean follow-up periods for these groups varied from 2.0-6.3 years. The mean reduction in intraocular pressure following treatment varied from 7.9 mm Hg in the secondary open angle glaucoma group to 24.3 mm Hg in those with angle closure glaucoma. Pressure was controlled in 29.4% overall, ranging from 66.7% in the angle closure and primary open angle groups to 0% in the secondary open angle group. Of the painful eyes 71% were rendered comfortable, indicating that pain relief from cyclocryotherapy is not due solely to pressure control. 30% of the patients lost their vision following the procedure, phthisis occurred in 11.8% and four eyes (5.9%) went on to enucleation. Our results indicate that cyclocryotherapy affords good pain relief, without good pressure control, in various types of glaucoma. While there is an apparent high complication rate, visual loss and phthisis cannot be ascribed directly to the procedure, since these are eyes with a poor prognosis.

Entities:  

Mesh:

Year:  1990        PMID: 2310722      PMCID: PMC1042001          DOI: 10.1136/bjo.74.2.103

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Surgical intervention on the ciliary body; new trends for the relief of glaucoma.

Authors:  G BIETTI
Journal:  J Am Med Assoc       Date:  1950-03-25

2.  Cyclocryotherapy in advanced inadequately controlled glaucoma.

Authors:  A R Bellows; W M Grant
Journal:  Am J Ophthalmol       Date:  1973-04       Impact factor: 5.258

3.  Rubeosis iridis and neovascular glaucoma. Evaluation of cyclocryotherapy.

Authors:  R M Feibel; J F Bigger
Journal:  Am J Ophthalmol       Date:  1972-11       Impact factor: 5.258

4.  Anatomy of the ciliary body and cyclocryotherapy.

Authors:  M Prost
Journal:  Ophthalmologica       Date:  1984       Impact factor: 3.250

5.  Filtration surgery in the treatment of neovascular glaucoma.

Authors:  R C Allen; A R Bellows; B T Hutchinson; S D Murphy
Journal:  Ophthalmology       Date:  1982-10       Impact factor: 12.079

6.  Cyclocryotherapy in neovascular glaucoma.

Authors:  T Krupin; K B Mitchell; B Becker
Journal:  Am J Ophthalmol       Date:  1978-07       Impact factor: 5.258

7.  Value and limitations of cyclocryotherapy.

Authors:  G Brindley; M B Shields
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

8.  Cyclocryotherapy in the treatment of advanced glaucoma.

Authors:  J Caprioli; S L Strang; G L Spaeth; E H Poryzees
Journal:  Ophthalmology       Date:  1985-07       Impact factor: 12.079

9.  Eyes with end-stage neovascular glaucoma. Natural history following successful modified filtering operation.

Authors:  R Parrish; J Herschler
Journal:  Arch Ophthalmol       Date:  1983-05

10.  Effects of cyclocryotherapy on aqueous humor dynamics in cats.

Authors:  E J Higginbotham; D A Lee; S P Bartels; T Richardson; M Miller
Journal:  Arch Ophthalmol       Date:  1988-03
View more
  17 in total

1.  Long term results of diode laser cycloablation in complex glaucoma using the Zeiss Visulas II system.

Authors:  S Ataullah; S Biswas; P H Artes; E O'Donoghue; A E A Ridgway; A F Spencer
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

2.  An unusual presentation of aqueous misdirection.

Authors:  A Koukkoulli; R Rahman
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

3.  "Cyclodiode": results of a standard protocol.

Authors:  A F Spencer; S A Vernon
Journal:  Br J Ophthalmol       Date:  1999-03       Impact factor: 4.638

4.  Long-term success of ahmed glaucoma valve in refractory glaucoma.

Authors:  Mahmut Kaya; Zeynep Ozbek; Aylın Yaman; Ismet Durak
Journal:  Int J Ophthalmol       Date:  2012-02-18       Impact factor: 1.779

5.  Transscleral diode laser cyclophotocoagulation for the treatment of refractory glaucoma secondary to inflammatory eye diseases.

Authors:  T Schlote; M Derse; M Zierhut
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

6.  A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma.

Authors:  C C Murphy; C A M Burnett; P G D Spry; D C Broadway; J P Diamond
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

7.  Controlled Cyclophotocoagulation with diode laser in refractory glaucoma and long term follow up at King Abdulaziz University Hospital, Riyadh.

Authors:  Essam A Osman; Abdulrahman Al-Muammar; Ahmed Mousa; Hani Al-Mezaine; Saleh A Al-Obeidan
Journal:  Saudi J Ophthalmol       Date:  2010-01-07

8.  Long-term results from cyclocryotherapy applied to the 3o'clock and 9o'clock positions in blind refractory glaucoma patients.

Authors:  Byoung Seon Kim; Young Jun Kim; Seong Wook Seo; Ji Myong Yoo; Seong Jae Kim
Journal:  Korean J Ophthalmol       Date:  2015-01-22

9.  Long-Term Outcomes and Prognostic Factors of Trabeculectomy following Intraocular Bevacizumab Injection for Neovascular Glaucoma.

Authors:  Tomomi Higashide; Shinji Ohkubo; Kazuhisa Sugiyama
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

10.  Outcomes of Ahmed glaucoma valve and transscleral cyclophotocoagulation in neovascular glaucoma.

Authors:  Wesam S Shalaby; Allen Y Ganjei; Brian Wogu; Jonathan S Myers; Marlene R Moster; Reza Razeghinejad; Daniel Lee; Natasha N Kolomeyer; Tarek E Eid; L Jay Katz; Aakriti G Shukla
Journal:  Indian J Ophthalmol       Date:  2022-04       Impact factor: 2.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.